Blood cancers

Novel BCR-ABL1 inhibitor shows efficacy and less toxicity in heavily pre-treated CML

Patients with CML who have been heavily pre-treated with at least two and often three tyrosine kinase inhibitors (TKIs) have been shown to respond to the novel BCR-ABL1 inhibitor asciminib. In an Australian-led phase 1 dose escalation study published in the NEJM, 150 adults with mostly chronic phase CML received once daily or twice daily ...

Already a member?

Login to keep reading.

© 2021 the limbic